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Abstract 
Modulation of vessel growth holds great promise for treatment of cardiovascular 
disease. Strategies to promote vascularization can potentially restore function in 
ischaemic tissues. On the other hand, plaque neovascularization has been shown to 
associate with vulnerable plaque phenotypes and adverse events. The current lack of 
clinical success in regulating vascularization illustrates the complexity of the 
vascularization process, which involves a delicate balance between pro- and anti-
angiogenic regulators and effectors. This is compounded by limitations in the models 
used to study vascularization that do not reflect the eventual clinical target population.  
Nevertheless, there is a large body of evidence that validate the importance of 
angiogenesis as a therapeutic concept.  The overall aim of this Position Paper of the 
ESC Working Group of Atherosclerosis and Vascular biology is to provide guidance 
for the next steps to be taken from pre-clinical studies on vascularization toward 
clinical application. To this end, the current state of knowledge in terms of therapeutic 
strategies for targeting vascularization in post-ischaemic disease is reviewed and 
discussed. A consensus statement is provided on how to optimize vascularization 
studies for the identification of suitable targets, the use of animal models of disease 
and the analysis of novel delivery methods.   
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1. Basic principles ± vasculogenesis, angiogenesis, arteriogenesis 
 
Vasculogenesis describes the coalescence of mesoderm-derived angioblasts 
into the first primitive blood vessels 1. The process was first observed in quail embryos 
2, 3
 and subsequently shown to be conserved in other vertebrates including mouse 4, 5 
and zebrafish 6, 7. These studies revealed many similarities not only between the 
morphogenetic processes of early blood vessel formation, but also between the 
molecules coordinating these processes 8. Several signalling pathways, such as 
Notch9 10 and Sonic Hedgehog 11, were shown to influence the early differentiation of 
arterial and venous endothelial cells (ECs) from angioblasts. Vasculogenesis was 
initially thought to be limited to embryo, but current understanding is more nuanced. 
Early embryonic angioblasts and hemoblasts share a very similar gene signature and 
the endothelium is hemogenic during development, meaning that hematopoietic stem 
cells differentiate from endothelial cells 12. The opposite is also true, hematopoietic 
stem cells can be differentiated into endothelial cells 13.  
Angiogenesis is the creation of new vessels from pre-existing ones 14. Hypoxia 
is one of the key drivers of the process. It activates ECs to become more motile and 
protrude filopodia. Further angiogenic factors such as vascular endothelial growth 
factor (VEGF) strongly dilates small arteries and capillaries which is the primary mode 
of VEGF action at low concentrations (intussusception angiogenesis). At high 
concentrations of VEGF, sprouting angiogenesis is the preferred mode of action 15. To 
prevent ECs moving en masse, a particular type of ECs, known as tip cells, are 
selected to lead the advance 16. Neighbouring cells assume an ancillary role as stalk 
cells, which divide to elongate the new vessel and establish a lumen. This specification 
of tip and stalk cells is governed by the Notch signalling pathway 17, 18. The 
establishment of flow in newly formed vessels leads to mechanical signals (shear 
stress) that feedback to reduce angiogenic sprouting thereby preventing excessive 
vascular growth 19, 20. 
Once stenosis in a large main artery becomes hemodynamically significant, the 
elevation of shear stress against the wall of these arterioles induces their enlargement. 
This is described as arteriogenesis. The collateral circulation may subsequently 
develop into a functional vascular structure to ensure regional perfusion after the 
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ischaemic event, thus protecting the tissues against necrosis. Simultaneously, 
arterioles, venules, and arteriovenous anastomoses are formed, following the 
production of smooth muscle cells and of the extracellular matrix (ECM), which 
consolidates the walls of these vascular structures 21.  
 
 
2. Neo-vascularization: physiology and pathophysiology 
 
2.1 Post-ischaemic angiogenesis: a physiological adaptation 
After the onset of ischaemia, cardiac or skeletal muscle undergoes a continuum of 
molecular, cellular, and extracellular responses that determine the function and the 
remodelling of the ischaemic tissue. Hypoxia-related pathways, the alterations in 
immunoinflammatory balance, as well as changes in hemodynamic forces within the 
vascular wall trigger vasculogenesis, angiogenesis and arteriogenesis which act in 
concert to establish a functional vascular network in ischaemic zones 22.  
The principal signalling pathway induced by hypoxia involves activation of 
hypoxia-induced factor (HIF1Į), which induces the expression of a set of genes 
appropriate to UHVSRQG WR WKLV VLWXDWLRQ ,QGHHG +,)Į FRQWUROV WKH H[SUHVVLRQ RI
numerous major players involved in angiogenesis and vascular remodelling, including 
VEGF. Moreover, the target genes of HIFĮ are involved in metabolism, 
erythropoiesis, pH homeostasis, and autophagy 23.  
During ischaemia, inflammatory cells release angiogenic factors (e.g. VEGF) 
and cytokines (e.g. TNFD), that decrease EC junctions and  enhance vascular 
permeability to promote the recruitment of inflammatory cells 24, 25. Consistent with this 
relationship between angiogenesis and inflammation, several molecules that regulate 
inflammation have been implicated in new vessel formation 22. Changes in 
hemodynamic forces (mechanical forces linked to pressure and flow rate) occurring in 
collateral vessels in response to arterial occlusion also contribute to post-ischaemic 
vascularization 26. Recent studies suggest that flow dynamics control the localisation 
of sprouting in vessels 27. The location is not determined by on highest VEGF 
concentration, but by a combination of VEGF and biomechanical signals 28. Thus, 
shear-induced mechanism appears to override pro-angiogenic signals such as VEGF 
29
.  These pathways can also participate in vascular pathology; for example, the 
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mechanosensitive transcription factor TWIST1 promotes angiogenesis in the embryo 
and is also required for plaque formation in atherosclerosis models 20.  
In patients with ischaemic diseases in the presence of comorbidities such as 
diabetes, hypertension and obesity, most of the cellular and molecular mechanisms 
involved in the activation of vessel growth and vascular remodelling are markedly 
impaired 22. Thus, in the last decades, stimulation of vessel growth has emerged as a 
novel therapeutic option in patients with ischaemic diseases 30.  
 
2.2 Plaque vascularization and pathophysiology 
Under physiological circumstances, microvessels originate from the adventitia 
and provide the media with oxygen and nutrients 31. However, microvessels in 
atherosclerotic plaques have been implicated in progression of the disease and 
adverse outcomes. 
It is postulated that plaque angiogenesis is driven by plaque hypoxia and 
inflammation  32, 33 34. In experimental models plaque angiogenesis has been induced 
by stress 35, 36, treatment with pro-inflammatory mediators 37, pro-angiogenic growth 
factors 38 and viral gene delivery of pro-angiogenic factors 39-43, and was shown to 
increase plaque burden. Besides an increase in the number of microvessels, the 
physiological properties (quality) of the microvessel are also associated with risk for 
human plaque rupture. Microvessels of ruptured plaques in coronary arteries 
displayed detachments of the endothelial junctions, endothelial membrane blebs and 
a thin or absent endothelial basement membrane, and surrounding pericytes were 
found to be absent in a majority of microvessels in ruptured plaques.44 These 
ultrastructural characteristics suggest vascular leakage 45, that might be responsible 
for increased extravasation of immune cells and deposition of lipids and red blood cells 
in the plaques 46-48. Therefore, these microvessels are thought to represent one of the 
main sources of intra-plaque haemorrhage, in addition to healed thrombi 49.  
 
3. Vascularization therapeutics 
 
3.1 Growth factor therapy 
Various growth factors have been applied for therapeutic angiogenesis 
including VEGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor 
(HGF), Platelet-derived growth factor (PDGF), stromal derived factor 1 (SDF-1), 
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Angiopoietin 1 (ANG-1) and insulin-like growth factor (IGF-1). Among these, VEGF 
and bFGF are the best studied and have reached human clinical trials. VEGF is the 
most important regulator of physiological angiogenesis during growth, healing and in 
response to hypoxia. VEGF is upregulated 30-fold by HIF1D, which is more than any 
other inducible angiogenic factor during ischaemia. However, when administered 
alone, VEGF could increase endothelial permeability which leads to the formation of 
leaky capillaries and tissue oedema 50.  
PDGF can help stabilize nascent blood vessels by recruiting mesenchymal 
progenitors, and co-delivery of VEGF and PDGF has been shown to lead to early 
formation of mature vessels in animal models 51. bFGF is among the first discovered 
angiogenic factors to have both angiogenic and arteriogenic properties, which may 
facilitate formation of a mature blood vessel network 52. The HGF family induces potent 
angiogenic responses by binding to the c-MET receptor, which is expressed on ECs, 
vascular smooth muscle cells and hematopoietic stem cells. HGF is known to have 
mitogenic, angiogenic, anti-apoptotic, and anti-fibrotic activities in various cells 53. 
Clinical trials of SDF-1 in critical limb ischaemia (CLI) patients are underway and a 
better understanding of the mechanisms of chemokines, especially SDF-1, is crucial 
in filling the missing link in growth factor studies in therapeutic angiogenesis 54  .   
Notably, most of the intervention strategies to manipulate angiogenesis in 
atherosclerosis have been restricted to mouse models by using antiangiogenic or 
proangiogenic molecules such as halidomide 55, TNP-470 56, angiostatin 57, 58, anti-
VEGF-A 59, bFGF 38 and VEGF-A 60. 
 
3.2 Cell therapy 
Since the first pilot clinical study to evaluate treatment of peripheral vascular 
disease with stem cell therapy in 2002, over 50 clinical studies have been reported 
with progenitor cells 61. Therapeutic details such as patient selection, effective cell type 
selection and processing, optimal dosage, and delivery route are constantly improved.  
Studies have included patients of varying peripheric artery disease (PAD) 
severity. However, most of clinical trials have primarily focused on CLI patients in small 
phase I or II studies 61.  A variety of cell types have been studied as potential PAD 
treatments, including unselected bone marrow mononuclear cells (BM-MNC) or 
peripheral blood MNC (PB-MNC), marker-specific cells selected from the marrow or 
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blood, mesenchymal stem cells (MSCs), and adipose tissue±derived regenerative 
cells 62.  
In clinical studies of neovascularization considerable progress in the use of 
adult stem cells for cell transplantation has been made using hematopoietic stem cells 
(HSC), bone marrow-derived dendritic cells (BMDC), MSC, and endothelial progenitor 
cells (EPC) 63. Neovascularization in infarcted heart can be mediated by the 
incorporation of vascular progenitor cells into the capillary or by the paracrine factors 
released from stem cells and progenitor cells. In relation to the effectiveness of the 
use of adult stem cells for cell transplantation, the variability in the reported findings 
may be partly explained by differences in the delivery methods, treatment logistics, 
and target diseases 63.  
 
 
3.3 Non-coding RNA therapy 
Short (microRNAs; miRNAs) or longer (long non-coding RNA (lncRNAs) non-
coding RNAs play important roles in several physiological and pathological conditions 
such as cancer and cardiovascular diseases (CVD) including atherosclerosis 64 . 
Emerging data show that several miRNAs are linked to both adaptive and maladaptive 
vascular remodelling processes. Mir-126, one of the most abundantly expressed 
microRNAs in ECs, has a pro-angiogenic as well as anti-atherosclerotic role 65 and the 
systemic delivery of miR-126 mimics rescued EC proliferation at vulnerable sites and 
inhibited atherosclerotic lesion progression 66. On the other hand, the 17-92 miRNA 
cluster is anti-angiogenic but pro-atherosclerotic. Recent studies described that the 
endothelial-specific deletion of miR-17-92 in mice enhanced arterial density and 
improved post-ischaemia blood flow recovery 67. Notably, miR-503 expression is 
increased in ischaemic limb muscles and ECs of diabetic mice. Inhibition of miR-503 
by adenoviral delivery to the ischaemic adductor muscles of diabetic mice corrected 
diabetes-induced impairment of post-ischaemic angiogenesis and blood flow recovery 
68
. Even though the functions of individual microRNAs in angiogenesis are not yet 
completely elucidated, because a single microRNA could regulate several growth 
factors at the same time, miRNA-derived therapy could replace single-factor 
angiogenic gene therapy 69.  
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4. Animal models of angiogenesis 
 
4.1 Pre-clinical studies of therapeutic angiogenesis 
Models to investigate post-ischaemic angiogenesis have been established in 
rodents and larger animals such as rabbits, pigs or dogs. They exhibit considerable 
variation because each species differs in the extent of naïve vascularization and thus 
reacts differently to vascular growth stimuli. To make things more complicated, within 
one animal species, different strains show distinct naïve vascularization and even 
show opposite reactions 70. 
So far, most studies have been performed in mice, because of the availability 
of a wide range of genetic knockout strains and the ease of introducing new genetic 
manipulations, including knock-in and temporal or tissue-specific manipulations. 
Moreover, the breeding is relatively fast and less expensive than experimentation with 
large animals and data obtained in mouse models are still necessary to justify 
experiments in large animal.  
A commonly used method in mice to induce post-ischaemic angiogenesis is the 
hind-limb ischaemia model, which is based on ligation of the femoral artery 71. 
Compared to the coronary or carotid artery, the femoral artery is easier to access and 
the method is accompanied by lower mortality rates. Moreover, live imaging of blood 
flow in ischaemic areas can be easily performed by laser Doppler imaging. 
Nevertheless, many of the mechanisms underlying neovascularization in response to 
ischaemia in peripheral arteries are not directly transferable to angiogenic processes 
in the heart. Experimental models of cardiac ischaemia are based on transient or 
permanent occlusion of the left descending coronary artery, induced by a highly 
invasive surgical procedure requiring thoracotomy. Moreover, in vivo imaging of 
coronary arteries by for instance intravital microscopy is complicated by the rapid 
movements due to cardiac and respiratory cycles 72.  
Rat models are also frequently used due to the ease of breeding and their 
extended lifespan. The methods and readouts normally applied do not differ 
essentially from those used in mice. Their major advantage compared to mice 
therefore lies in their size, without improving translatability into humans. Moreover, 
larger animals require a longer time to restore vessel function by neovascularization. 
Of course, this is an oversimplification, but it partly explains why larger animal models 
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are often regarded to have added value for translation of angiogenic therapies into 
human medicine (Table 1).  
For a long time, the dog 73, 74 , together with the rabbit 75, 15, were the animals 
of choice for investigation of neovascularization. Amongst other reasons such as easy 
handling, dogs are well known for their extended myocardial vascularization that 
allows performing coronary artery occlusions with low complication rates. Much of our 
current knowledge on the role of various angiogenic and arteriogenic growth factors is 
based on experiments performed in dogs. However, ethical considerations have led 
to a significant decrease in the use of dogs for animal experimentation.  
The occlusion pathophysiology and tissue recovery that occur after an acute 
arterial ligation are very different in animal models than in human chronic ischaemic 
diseases. Experimental acute vessel occlusion results in an immediate vascular 
response in animals which reflects the situation in a limited subgroup of patients (such 
as young patients with traumatic injuries), who require immediate medical 
interventions and are not typically enrolled in angiogenic therapy clinical trials. Another 
crucial difference between the experimental models and patients is that the patients, 
owing to their comorbidities, do not have sufficient growth of collaterals, showing  
decreased endogenous angiogenic stimuli and reduced angiogenic signalling 30.  
The search for an adequate replacement with potentially even higher 
translational value has resulted in an increasing number of pig models. Hind-limb 
ischaemia in pigs can be safely performed without leading to limb necrosis 76. In 
contrast, the pig was long considered to have insufficient capabilities to compensate 
for coronary ischaemia by neovascularization 77. In the past decade, however, several 
groups succeeded in establishing also pig coronary neovascularization models by 
inducing progressive coronary stenosis rather than acute occlusions78, 79.  
 
4.2 Pre-clinical studies of plaque angiogenesis 
Many studies of atherosclerosis use murine models, however there are several 
limitations in their applicability to analyse plaque vascularization. Notably, 
atherosclerotic plaques developing in hypercholesterolemic murine models contain 
fewer microvessels than human atherosclerotic plaques. The reason for this remains 
uncertain but it may be due to differences in the transport of oxygen between human 
versus murine atherosclerotic plaques, ECM turnover and different biomechanics 
between mice and man 80. A role for ECM was implicated by studies of knockout mice 
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lacking collagen XVIII which had enhanced intra-plaque vascularization in response 
to hypercholesterolemia compared to controls 57. This was more pronounced in ApoE 
fibrillin double knockout mice 81, suggesting that lack of proper ECM components in 
the media  and plaque might mediate angiogenesis. Besides ECM degradation, 
different biomechanical properties between mice and man might also explain the lack 
of plaque angiogenesis 82, 83. Lower fibrotic material stiffness (cellular and 
hypocellular) and a fundamental difference in plaque morphology (dome-like) together 
with a smaller vessel size as well as lower peak cap stress are present in murine 
compared to human plaques 83. In addition, tissue contraction and deformation have 
been shown to induce VEGF-A expression 84. Lower biomechanical stresses might 
account for lower VEGF-A levels in mice versus humans. Indeed, ruptured human 
plaques express higher levels of VEGF-A compared to stable plaques 85. In murine 
atherosclerosis, experimental overexpression of VEGF-A increased signs of plaque 
vulnerability 38, showing that endogenous VEGF-A expression is not sufficient to evoke 
signs of plaque rupture.   
Another limitation relates to the site of microvessel formation. While a minority 
of studies report intra-plaque angiogenesis in murine atherosclerosis models, most 
focus on plaque-associated vasa vasorum of the adventitia as a surrogate for intra-
plaque microvessels (Table 2). This is an important caveat because although 
adventitial vasa vasorum growth may precede atherosclerotic plaque development 86, 
87
, plaque rupture has been linked with increased intra-plaque angiogenesis rather 
than an increase in adventitial vasa vasorum in humans 44. Thus far, this discrepancy 
limits the extrapolation of murine adventitial angiogenesis as an outcome parameter 
to human studies. 
Moreover, several methodological limitations hamper the comparability of 
murine and human studies. Firstly, while murine models usually examine on various 
regions (e.g. aortic root, ascending aorta, descending aorta, brachiocephalic artery, 
and carotid artery) they often ignore other clinically-relevant vessels such as the 
coronary and renal arteries. In addition to this, the parameters measured to assess 
vascularization vary considerably between studies: for example, microvessel density 
(number of microvessels per mm2), microvessel count (per section or per mouse), 
CD31 positive adventitial area or vasa vasorum volume have been used (Table 2). 
Moreover, also the imaging method varied between studies: most of them used 
histology, but also intra-vital microscopy, two photon microscopy, confocal microscopy 
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and micro CT have been used to visualize adventitial microvessels (Table 2). 
Moreover, the experimental design often limits the translatability of the findings. In two 
studies, induction/manipulation of angiogenesis was started together with 
atherosclerosis induction 55, 88, whereas pre-existing plaques represent the treatment 
target in human atherosclerosis.  
In addition to mice and rats, rabbits and pigs (Table 3) have been used to study 
angiogenesis in atherosclerosis. In rabbit models, atherosclerosis was mostly induced 
by a combination of balloon angioplasty and high cholesterol diet, leading to plaques 
with a baseline microvascular density between 15 and 80 vessels per mm2. In some 
studies, adventitial angiogenesis was specifically targeted using a hollow perivascular 
collar together with a relatively short post-operation time of 9 to 21 days 40, 41, 89, 90. 
Interestingly, induction of diabetes accelerated atherogenesis and intraplaque 
angiogenesis in Watanabe heritable hyperlipidemic rabbits 91 (Table 3). 
In pigs, atherosclerosis was induced by high cholesterol diet and/or surgical 
interventions (balloon angioplasty or stenting) (Table 3). However, intra-plaque 
angiogenesis was not detected in all studies except for one (Table 3). Here, a 
genetically engineered Yucatan mini pig was used, which develops 
hypercholesterolemia due to pro-protein convertase subtilisin/kexin type 9 (PCSK9) 
overexpression, when fed a high cholesterol diet 92. The resulting plaques show a 
human like morphology including intra-plaque and adventitial angiogenesis. However, 
data on microvascular density were unfortunately not provided. Practically, larger 
animal models allow for the use of clinical diagnostic tools such as magnetic 
resonance imaging to detect microvessels. Therefore, it will be easier to translate the 
study results to the human situation.  
 
5. Gene and cell delivery 
 
5.1 Viral delivery 
Gene and cell delivery into the myocardium has been a major challenge over 
the past decade. Efficient therapeutic approaches developed in animal models have 
not been successful in human clinical trials because gene and cell transfer efficiency 
in cardiac muscle has remained too low 93, 94 Several factors contribute to this problem: 
the human heart is a very large muscle as compared to mice and rats and vectors or 
cell solutions cannot easily penetrate deep into the myocardium. The adeno 
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associated virus (AAVs) for instance, bind tightly to heparansulphate proteoglycans 
and they do not easily escape from the intraluminal space into the myocardium 95. In 
previous trials, intracoronary injections, intramyocardial injections from the left 
ventricle and intramyocardial injections during thoracotomy or bypass surgery have 
been tested. However, because occluded coronary arteries do not get adequate 
perfusion, fail to deliver substances into the ischaemic areas. Thus, it is not surprising 
that intracoronary injections have not been very successful for gene and cell delivery.  
 
5.2 Mechanical delivery 
Intramyocardial injections lead to better transduction efficiencies but diffusion 
of viral vectors in the myocardium is still limited and the binding to ECM components 
further limits vector spreading in the myocardium. Protein, such as VEGF-A165, 
delivered by transgenes, bind strongly to heparansulphate proteoglycans which 
reduces their diffusion in ischaemic and fibrotic myocardium.  Similar obstacles exist 
for successful cell delivery into the myocardium. Intracoronary injections seldom lead 
to viable, engrafted cells in the heart. Intramyocardial injections cause significant 
mechanical stress on the cells during injections. Most cells seem to die within hours 
or during the first days and paracrine factors seem to contribute to the potential 
therapeutic effects 96, 97. For applications like myocardial ischaemia, local targeted 
injections based on electromechanical mapping 98 or blood flow measurements using 
positron emission tomography 98 have recently improved the situation and targeted 
injections into hibernating myocardium can now be achieved with 10-20% efficiency 
around the needle track. Multiple injections are still needed to cover larger areas in 
ischaemic myocardium. To improve myocardial function in heart failure, the effects of 
gene or cell transfer should be very global to transduce as many cardiomyocytes as 
possible. At the moment, this can be achieved with some vectors in mice 99 but in 
larger animals and humans wide spread gene expression after any delivery method 
still remains a very challenging task 100, 101. 
 
5.3 Non-viral delivery 
Several methods of non-viral gene transfer have been utilized to deliver genes 
of interest to ischaemic tissues to stimulate therapeutic angiogenesis. Genes encoding 
pro-angiogenic proteins have been administered by cationic polymers, lipids, 
liposomes and three-dimensional scaffolds 102. Targeting strategies using polymers or 
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lipids modified with specific ligands for the receptors on target tissues could improve 
the efficacy of current gene delivery systems by facilitating cellular uptake of genes 
via receptor-mediated endocytosis 103. Gene delivery using lipid formulations has been 
applied in ischaemic tissues for therapeutic angiogenesis. Jeon et al. reported that 
VEGF-A gene delivery using heparin-conjugated Polyethylenimine (PEI) significantly 
upregulated VEGF-A expression, resulting in extensive neovascularization in mouse 
ischaemic limbs 104. Nanoparticles composed of biocompatible and biodegradable 
polymers (e.g., poly (lactic-co-glycolic acid; PLGA) are considered to serve as gene 
carriers for the treatment of ischaemic tissues due to the efficient delivery mechanism 
and low toxicity. Indeed, VEGF-A delivery using PLGA nanoparticles resulted in higher 
VEGF-A expression and more extensive angiogenesis in mouse ischaemic limbs 105. 
A novel concept of involving a biodegradable gelatin hydrogel carrying a sustained-
release system of bFGF was studied in patients with CLI. The delivery improved 
transcutaneous oxygen tension, increased walking time, and decreased ischaemic 
pain 106. Despite this progress, the ability to introduce new genes into ischaemic tissue 
remains an important challenge and a limiting factor in the field of therapeutic 
angiogenesis. 
 
6. Clinical trials for therapeutic vascularization: change of perspectives 
 
6.1 Endpoints 
Ongoing clinical gene and cell therapy trials have been reviewed elsewhere 93, 
107
.  In most ongoing trials, very stringent endpoints have been selected, such as 
overall mortality, major adverse cardiovascular events (MACE), improvement in 
exercise test, or various quality of life endpoints. However, since most gene and cell 
therapy trials are still quite small as compared to large pharmaceutical phase II/III 
trials, endpoints like overall mortality or MACE cannot easily capture potentially 
significant treatment effects, such as reduced frequency of hospital admissions and 
lower number of multiple additional interventions in chronically ill patients. For 
example, endpoints like ST segment decline of 1 mm is not useful for refractory angina 
patients who usually have infarction scars, ECG alterations and the ST segment 
changes cannot be reliably detected.  Small phase I and phase II clinical trials for CLI 
have shown that cell-based therapies are safe and improve wound healing, but the 
trials were not large enough to detect any improvements in delaying amputation 62. 
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Ideally, functional readouts based on imaging such as PET or MRI should be 
obtained ahead of hard clinical endpoints to validate the biological effects of the 
intervention along the way.  It would be especially important to measure functional 
improvements in the myocardial function and extend analysis to various sensitive 
imaging and metabolic measurements. In cancer trials for example, it is well accepted 
that drugs can be approved based on imaging-derived complete or partial responses 
and/or timelines to recurrence even though there are no effects on survival or mortality 
108
. In addition, it is likely that only some patient populations will be responding 
positively to gene and cell therapies and therefore it would be important to identify 
biomarkers, which could differentiate responders from non-responder populations 109. 
 
6.2 Patient populations 
So far, while non-controlled, non-randomized gene and cell therapy trials in 
cardiovascular diseases have provided positive outcomes, most randomized, 
controlled, blinded studies have not achieved any clinically relevant effects in heart 
and limb muscles 110.  In multi-center studies, heterogeneity in patients and different 
cell preparations and products can influence the efficacy of cell therapy 111.  In addition, 
meta-regression showed that a refinement in endovascular and surgical techniques 
leading to improved limb salvage is expected to reduce the potential incremental 
benefit of cell therapy 111 . Therefore, future cardiovascular gene and cell therapy trials 
should focus more on randomized, blinded and controlled study designs where less 
severely affected patients are treated as compared to so called no-option patients 
which have been frequently targeted in previous non-randomized trials. It is likely that 
these no-option patients have already lost at least some of their regenerative capacity 
and therefore are not optimal for testing new biological therapeutic approaches.  
 
6.3 Growth factors development 
To achieve better outcomes, an optimal profile of growth factors should be 
identified for clinical testing since some of the previously tested factors, such as VEGF-
A, are problematic in respect to their fast and very strong effects. They also induce 
harmful side effects like increased vascular permeability and thrombosis. Despite 
promising effects of anti VEGF therapy on tumor angiogenesis, serious adverse 
effects on cardiovascular events (angina pectoris, arterial thrombosis, cerebral or 
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myocardial ischaemia and infarction) have been shown for the VEGF-A inhibitor 
bevacizumab in a meta-review study 112. 
 Instead, growth factors with more appropriate signaling kinetics for improving 
cardiac condition should be taken into clinical testing. A possible example is VEGF-D, 
which is both angiogenic and lymphangiogenic and therefore can improve fluid 
drainage from myocardium after inducing angiogenic effects. Signaling kinetics for 
VEGF-D are also slower, less aggressive and longer lasting than VEGF-A. Therefore, 
it may be better suited for therapeutic applications than the previously tested growth 
factors. Recent phase I/IIa clinical trial results in refractory angina patients have indeed 
supported this approach. The trial results showed improved myocardial perfusion 
reserve in the treated ischaemic, hibernating myocardium one year after the treatment 
113
. Also, the trial suggests that patients with high Lp(a) benefit most from the 
adenovirus VEGF-D therapy. Therefore, we can expect improved therapeutic 
applications in the future after learning important lessons from the previous trials.  
 
Consensus statement:  
The design of therapeutic strategies for angiogenesis is crucial to the success 
of the vascularization studies. In this section, the ESC Working Group for 
Atherosclerosis and Vascular Biology provides guidance for the development of 
treatments to target the vasculature in post-ischaemic disease and for their 
assessment in pre-clinical and clinical studies: 
 
x Research during the last decade has identified an intricate genetic network of 
molecules that control the assembly of the first blood vessels from individual 
angioblasts prior to the onset of circulation. Moreover, large-scale changes in 
transcriptomes as well as changes in non-coding RNAs that regulate the 
angiogenic process have been investigated. The potential to harness these 
novel mechanisms to drive therapeutic angiogenesis should now be tested. 
x Although murine models have underpinned a wealth of basic biology studies, 
they also have certain limitations (reviewed extensively above). Standardization 
of animal models for cardiovascular research and inclusion of comorbidities are 
necessary to reach the standard for clinical translation. It is our view that large 
animal models, including novel transgenic pig models, can be useful for long-
term experimentation because their close similarity with human size, anatomy 
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and metabolism enhances their relevance for clinical translation. Main 
limitations for the use of large animal models could be the costs and ethics 
behind such studies.   
x Efficacy and tissue specific delivery is a key point to consider in planning 
neovascularization studies. It appears that physical/mechanical interventions 
(i.e., by surgery or via a catheter) currently provides better control for the 
delivery procedure compared to systemic injection. In the setting of PAD or 
coronary artery disease (CAD), local cell or gene therapy to promote post-
ischaemic angiogenesis could be combined with systemic pharmacological 
therapy to reduce risk factors for atherosclerosis. A new generation of inducible 
viral vectors should be developed to allow precise temporal control of inducible 
transgene expression, thus avoiding detrimental effects due to continuous 
overexpression. As an alternative, non-viral gene transfer, has become a 
possible option for transgene delivery.  
x An analysis of the clinical trial of the last decades has shown that endpoints 
have been inconsistently used in clinical trials. We propose that functional and 
metabolic readouts should be further developed to capture therapeutic efficacy 
and biological activity of the treatments and support clinical hard endpoints.  To 
this end, imaging readouts represent one avenue for the future that will require 
further standardization.  
x Patient selection is critical, given the influence that comorbidities, aging and 
medications may have on the results of the trials. Since safety of gene and cell 
therapy has been very good in almost all reported trials, moving towards trials 
of less severe patients, such as CCS class 2-3 for refractory angina, in the 
future will be justified. Biomarkers and scores that would enable appropriate 
identification of specific target populations that benefit most from gene or cell 
therapy need to be proposed. Finally, further genetic characterization of non-
responder patient groups in neovascularization clinical trials would help to 
identify factors affecting treatment responsiveness. 
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Figure Legend 
Figure 1: Difference in heart vascularization and response to ischaemia between 
animals and humans 
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Table 1: Large animal models of post-ischaemic angiogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Animal 
Species 
Model Outcome Ref. 
R
a
b
b
it
 
Left anterior descending coronary artery ligation Myocardial Infarction  75
 
Femoral artery ligation Hind-limb ischaemia 15
 
Femoral artery excision Hind-limb ischaemia 114
 
P
ig
s 
Coronary stenosis Myocardial Infarction 78, 79
 
Left anterior descending coronary artery ligation Myocardial Infarction 77
 
Femoral artery ligation Hind-limb ischaemia 76
 
D
o
g
 Ameroid constrictors and coronary artery ligation Myocardial Infarction 73
 
Ameroid constrictors Myocardial Infarction 74
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Table 2: Model of angiogenesis in mouse atherosclerotic plaque 
 
Animal 
Species 
Anti/Pro 
Angiogenic 
Mechanism Duration Read 
out 
Effect 
on 
plaque 
Intra-
plaque 
Incidence Adventitial Incidence Ref. 
S
h
o
rt
 t
im
e
 d
ie
t  
ApoE-/- Pro Time + hr 
VEGF-A 
7, 6, 5 
wks HCD 
Histo ј ј ND ND - 38 
LDLR-/- Anti Time + VEGF 
R2 
vaccination 
20 wks 
HCD 
Histo љ ND - љ ND 88 
LDLR-/- 
ApoB38-/- 
Pro Time + 
VEGF-A, 
VEGF-B, 
VEGF-C, 
VEGF-D  
genetransfer 
12 wks 
HCD 
Histo = - - = 5 
vessels/section 
43 
ApoE-/- 
Coll XVIII-
/- 
Pro Time + 
CollXVIII KO 
24 wks 
HCD 
Histo ј ј Incidence, baseline 
13% and KO 53% 
ј Baseline 17% 
vessels/area 
and KO 32% 
vessels/area 
57 
ApoE-/- 
Fbn1 
C1039G+/- 
Pro Time + Fbn1 
C1039G+/- 
KO 
20 wks 
HCD 
Histo ј ј Incidence, baseline 
4% and KO 90%, 
baseline MVD 0 and 
KO MVD 6 
vessels/10^7 µm2 
Present ND 81 
A
g
e
d
 m
ic
e
 a
n
d
/o
r 
p
ro
lo
n
g
e
d
 d
ie
t 
ti
m
e
 
ApoE-/- - Time 40-50 
wks 
chow 
Two 
photon 
micro. 
- ј Incidence 30% ј Incidence 
88.2% 
48 
ApoE-/- Pro Time + 
rbFGF 
(I) 67-94 
wks 
chow (II) 
12 wks 
HCD 
Histo ј ND - ј ND 60 
ApoE-/- - Time 40-96 
wks HCD 
Intravital 
micro. 
- ј 5% 2 of 39 studied 
advanced plaques 
(but total mice 
imaged 168 mice 
ј Incidence 77% 47 
ApoE-/- 
LDLr-/- 
Anti Time + 
Thalidomide 
39 wks 
chow 
µCT љ ND - љ Baseline 8 
vessels/section, 
treatment 5.5 
vessels/section 
55 
ApoE-/- 
SV129-/- 
Pro Time + 
stress + 
SV129 KO 
20 wks 
HCD 
Histo ј ј ND ND - 35 
S
u
rg
ic
a
l 
M
a
n
ip
u
la
ti
o
n
 
ApoE-/- - Collar 
Placement + 
MMP9 gene 
therapy 
Not 
clear 
Histo = = ND ND - 39 
LDLr Anti Collar 
placement + 
VEGFR2 
vaccination 
Not 
clear 
Histo љ - - Present ND 115 
ApoE-/- Pro Collar 
placement + 
VEGF-A 
genetransfer 
Not 
clear 
Histo ј = ND = ND - 39 
LDLr Anti Collar 
placement  
+ Tie2 
vaccination 
8 wks 
HCD 
Histo љ - - љ Baseline 22 
vessels/section, 
treatement 7.5 
vessels/section 
116 
ApoE-/- - Tandem 
Stenosis 
17, 13, 
10, 8 
wks HCD 
Histo ј Present 0.03 
microvessels/mm2 
Present ND 117 
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Table 3: Large animal models of plaque angiogenesis 
 
 
 
 
ApoE-/- Pro Wireinjury + 
asTF 
genetransfer 
6 wks 
HCD 
Histo ј ј Baseline 0.5 
vessels/mm2, 
treatment 1.75 
vessels/mm2 
ND - 42 
Animal 
Species 
Anti/Pro 
Angiogenic 
Mechanism Duration Read 
out 
Effect 
on 
plaque 
Intra-
plaque 
Adventitial Ref. 
R
a
b
b
it
s 
Pro Time +hrVEGF-A 6 wks 
HCD 
Histo ј Increase 
but only 
total CD31 
measured 
not density 
ND 38 
Pro Perivascular Collar + 
VEGF-A, VEGF-CNC, VEGF-
D and VEGF-DNC gene 
transfer 
3 wks 
HCD 
Histo ј ND ј 40 
Pro Perivascular Collar + 
VEGF-E, VEGF-E+(s)VEGF-
R-2 gene transfer 
10 days 
chow 
Histo ј ND ј 89 
Pro Collar placement (rabbit)+ 
balloon angioplasty (rat) 
with VEGF and PR39 gene 
transfer 
9 days 
(rabbit) 
and 14 
days 
(rat) 
chow 
Histo ј ND ј 41 
Pro Watanabe + Alloxan 
injection to induce 
diabetes 
 Histo 
NMR 
ј Total CD31 
not density 
ND 91 
P
ig
s 
Anti Time + Thalidomide 
4mg/kg 
12 wks 
HCD 
µCT љ ND љ 32 
Anti Balloon Angioplasty + 
Endostar 
12 wks 
HCD 
Histo љ ND љ 118 
- Time + PCSK9 KI 46 wks 
HCD 
Histo - Present Present 92 
